|
Showing 1 - 5 of
5 matches in All Departments
The term phytomedicine was coined by French physician Henri Leclerc
in 1913. Till recently phytomedicine has remained in the
background. But due to emerging challenges to the conventional
pharmaceutical industry (cost effectiveness and potency of the
drugs), phytomedicine has made a dramatic comeback. Phytomedicine
has witnessed several changes and several new concepts have been
introduced. Phytomedicine, although, a separate discipline, is
strongly linked to Phytotherapy and Phytopharmacology. As the title
suggests the book is an attempt to bridge the gap between
fundamental and emerging concepts in this field of medicine. The
book has been divided into two parts. Part A deals with core issues
of the phyto-pharmaceutical drug industry. The book begins with an
introductory chapter dealing with basic definitions with
phytomedicine. Chapters 2-5 narrate emerging subjects such as
Phytopharmacovigilance, Phytopharmacoeconomics,
Phytopharmacoepidemiology and Phytopharmacogenomics. Chapter 6
discusses ethical issues in phytomedicine. Chapter 7 covers recent
advances in drug delivery systems in phytomedicine whereas Chapter
8 is about application of nanotechnology in the field of
phytomedicine. The further chapters cover metabolomics, regulatory
and legal aspects of the phyto-pharmaceutical drug industry. The
chapter on herbal bioavailability enhancing agents is the salient
feature of Part-A. Part B is related to applied research in the
field of phytomedicine. Experimental findings on phyto-bioactive
agents such as withanolides, steroidal alkaloids, phytosteroids and
phytocannabinoids have been elaborated. Nine annexures related to
herbal drug registration are included.
Reverse Pharmacology: Phytocannabinoids, Banned and Restricted
Herbals will serve as a tailormade reference guide for the
manufacturers and practitioners of herbal drugs. Part A deals with
Reverse Pharmacology & Nanophytomedicine and Part B with
Phytocannabinoids and description of banned or restricted herbal
drugs. Part B also includes chemical structures and unpublished
material which are the salient features of this book. The work is
an invaluable resource for professionals in the manufacturing of
herbal and pharmaceutical products as well as those persons in
regulatory affairs.
Reverse Pharmacology: Phytocannabinoids, Banned and Restricted
Herbals will serve as a tailormade reference guide for the
manufacturers and practitioners of herbal drugs. Part A deals with
Reverse Pharmacology & Nanophytomedicine and Part B with
Phytocannabinoids and description of banned or restricted herbal
drugs. Part B also includes chemical structures and unpublished
material which are the salient features of this book. The work is
an invaluable resource for professionals in the manufacturing of
herbal and pharmaceutical products as well as those persons in
regulatory affairs.
The term phytomedicine was coined by French physician Henri Leclerc
in 1913. Till recently phytomedicine has remained in the
background. But due to emerging challenges to the conventional
pharmaceutical industry (cost effectiveness and potency of the
drugs), phytomedicine has made a dramatic comeback. Phytomedicine
has witnessed several changes and several new concepts have been
introduced. Phytomedicine, although, a separate discipline, is
strongly linked to Phytotherapy and Phytopharmacology. As the title
suggests the book is an attempt to bridge the gap between
fundamental and emerging concepts in this field of medicine. The
book has been divided into two parts. Part A deals with core issues
of the phyto-pharmaceutical drug industry. The book begins with an
introductory chapter dealing with basic definitions with
phytomedicine. Chapters 2-5 narrate emerging subjects such as
Phytopharmacovigilance, Phytopharmacoeconomics,
Phytopharmacoepidemiology and Phytopharmacogenomics. Chapter 6
discusses ethical issues in phytomedicine. Chapter 7 covers recent
advances in drug delivery systems in phytomedicine whereas Chapter
8 is about application of nanotechnology in the field of
phytomedicine. The further chapters cover metabolomics, regulatory
and legal aspects of the phyto-pharmaceutical drug industry. The
chapter on herbal bioavailability enhancing agents is the salient
feature of Part-A. Part B is related to applied research in the
field of phytomedicine. Experimental findings on phyto-bioactive
agents such as withanolides, steroidal alkaloids, phytosteroids and
phytocannabinoids have been elaborated. Nine annexures related to
herbal drug registration are included.
|
You may like...
Loot
Nadine Gordimer
Paperback
(2)
R398
R330
Discovery Miles 3 300
|